Kornimate/medical-research-clean huggingface dataset:
effectiveness of different approaches for the rehabilitation of gait in patients with parkinson's disease

Conditions: PD; Gait Dysfunction, Neurologic; Rehabilitation

Summary: evaluation of the effectiveness of three different approaches for the rehabilitation of gait in patients with pd within a multidisciplinary, intensive rehabilitation treatment (mirt).

gait disorders represent one of principal hallmark of parkinson's disease (pd). typically, pd patients demonstrate reduced stride length and walking speed during free ambulation, while double support duration and cadence rate are increased. gait disorders are generally poorly responsive to dopaminergic treatments and are related to reduced quality of life and augmented risk of falls. different rehabilitation techniques based on compensatory and learning strategies, which principally exploit the use of cues to bypass the defective basal ganglia and to ameliorate performance through practice, have been demonstrated to be effective in improving gait in patients with pd. cueing techniques represent the central core for the rehabilitation of parkinsonian gait. in this context, it has been demonstrated that treadmill training can improve gait performance in pd patients. it probably acts as an external cue exerting a normalizing effect on the spatiotemporal gait parameters and leading to an enhanced gait rhythmicity and a reduced gait variability. the use of a treadmill with visual and auditory cues (treadmill-plus) seems to lead to a better improvement in gait parameters when compared to treadmill alone. recently, the application of virtual reality (vr) has been introduced in the rehabilitation of pd. the use of vr is based on the interaction of the person with a virtual environment with the aim to promote motor learning through enhanced perceptions (visual, auditory, and haptic inputs). it has been widely demonstrated that a multidisciplinary, intensive, goal-based, motor-cognitive and aerobic treatment (mirt), specifically designed for pd patients, provide parkinsonians with motor and functional benefits. nevertheless, the contribution provided by treadmill, treadmill-plus and vr on gait parameters has not been previously addressed within mirt. this study aims at investigating the superiority or the non-inferiority of these different devices in improving gait in pd patients in the context of mirt.

Eligibility criteria:
inclusion criteria: * diagnosis of "probable" idiopathic parkinson's disease according to gelb et al (gelb, 1999); * mild to moderate stage of disease (stage 2-3) according to hoehn \& yahr scale; * ability to walk on treadmill; * visual and hearing capacity sufficient to perceive the cues; * no cognitive impairment (mini-mental state examination score ≥ 26); * stable pharmacological treatment since 2 weeks before admission and during rehabilitation; exclusion criteria: * diagnosis of atypical or vascular parkinsonism; * occurrence of cardiovascular, orthopaedic, peripheral nerves, musculoskeletal and vestibular disorders which could affect patient's locomotion or balance; * neuropsychiatric disturbances; * severe dyskinesia; * severe freezing of gait;
phase iia safety and efficacy study of srd174 cream in patients with ad-associated pruritus

Conditions: Pruritus, Atopic Dermatitis

Summary: pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. itching has a significant impact on the quality of life of ad sufferers, in particular night-time itching leading to sleep disturbance and subsequent poor daytime performance. the objective of this study is to determine whether srd174 cream is a safe and effective therapy for moderate to severe pruritus associated with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * males and females aged 18 years and over moderate to severe ad pruritus * written signed and dated informed consent * satisfactory medical assessment with no clinically relevant abnormalities exclusion criteria: * subject with active and pruritic ad covering a body surface area (bsa) \> 20% * subject with severe ad defined as an iga score of 4 * subject with current or recurrent skin disease (except ad) that could affect the site of application of action, absorption or disposition of the investigational product, or clinical, laboratory assessments. * subjects with unstable or uncontrolled medical conditions that could require intensive treatment during the course of the study. * subject with known or suspected intolerance or hypersensitivity to the investigational products or any of the stated ingredients. * subject who has a medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with interpretation of trial results and, in the judgment if the investigator, would make the subject inappropriate for entry into this trial.
immunonutrition in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this study tests the hypothesis that a supplement that combines a functional fiber, long chain omega-3 polyunsaturated fatty acids (pufas), vitamin d3, vitamin e, and zinc will reduce clinical symptoms, decrease pro-inflammatory cytokines in the blood and ergo decrease inflammation, promote beneficial microbial activity in the colon, and help recovery of the intestinal mucosa of ulcerative colitis (uc) patients compared with a placebo.

an anticipated 30 participants with newly diagnosed active ulcerative colitis will be recruited to participate in a randomized control trial, with 50% of the subjects distributed to the supplement (n=15) and the other 50% provided a placebo control (n=15). this is considered as a "proof of concept" study to determine if there is evidence that a multi-ingredient supplement (immunonutrition) will reduce uc disease severity.

Eligibility criteria:
inclusion criteria: * patients with active ulcerative colitis (proof of diagnosis from gastroenterologist), over 18 years old, has over 50% gut remaining, fully connected bowels (no colostomy), currently on 5-aminosalicylates (asa) drugs, not pregnant or lactating exclusion criteria: -
a home-based blood pressure monitoring program to promote better management of hypertension

Conditions: Hypertension

Summary: in this study the investigators aim to evaluate the effect of home-based blood pressure measurement with an electronic device on medication adherence and blood pressure control.

adherence to treatment is disappointingly low among patients with chronic health disorders especially after 6 month of initiating drug therapy. in hypertensive patients , as reported by who, 50% of non-adherence could be expected. poor adherence to anti hypertensive medications results in increased morbidity, mortality and costs. one of the reasons that could implicate medications adherence can be attributed to seeing no physical sign of better controlling blood pressure. self monitoring of blood pressure at home has been reported to improve patients adherence to their medications. this study is a 2-arm randomized controlled trial. the investigators aim to evaluate the effect of home-based blood pressure measurement with an electronic device on medication adherence and blood pressure status. one hundred ninety six hypertensive patients aged at least 18 years old are recruited in an ambulatory care setting and are evenly allocated to the study arms with balanced-block telephone randomization. appropriate medication is prescribed as preferred by the cardiologist (single daily dose medicines are recommended). patients in both arms are followed for 24 weeks, each will be visited by the cardiologist four times during the study period. in each visit, patients' blood pressure will be measured twice by a nurse in the office. in the intervention arm, electronic blood pressure device is provided for each patient and he/she will be trained to measure blood pressure at home once daily (same time each day). a logbook is also provided to document the daily blood pressure level. primary outcome of the study is the blood pressure measured at each office visit overtime. medication adherence is measured by pill count method as the secondary outcome.

Eligibility criteria:
inclusion criteria: * ambulatory patients older than 18 * patients newly diagnosed as hypertension stage 1 * patients previously on antihypertensive treatment but uncontrolled hypertension * patients not possessing electronic self blood pressure measurement device * patients with functional ability to use the device exclusion criteria: * patients requiring two or more antihypertensive drugs at the start of the study * patients with secondary hypertension * patients cardiovascular comorbidities and other interfering medical conditions * patients with drug contraindication or documented drug allergy * patients with serum creatinine \> 150 microliters withdrawal criteria: * inadequate therapeutic effect requiring an increase of more than 20% in pre-established number of visits * emergence of adverse drug reactions requiring cessation of medication

Keywords: medication adherence blood pressure home-based blood pressure measurement blood pressure determination blood pressure monitors blood pressure monitoring, ambulatory
the association of cardiac valve calcification and 1-year mortality after lower-extremity amputation in diabetic patients

Conditions: Amputation; Diabetic Foot; Valve Disease, Aortic; Valve Heart Disease

Summary: the goal of this observational study is to learn about the association between cardiac valve calcification and the 1-year mortality after lower-extremity amputation in diabetic patients. diabetic patients requiring lower-extremity amputation were retrospectively studied. preoperative detailed anamnesis was taken. cardiac valve calcification was assessed using echocardiography at baseline. one-year follow-up was conducted and included clinical visits, hospital record assessment, and telephone reviews to obtain the survival status of patients. researchers compare the survival group to the mortality group to study the relationship between the cardiac valve calcification and mortality.

this study aimed to investigate the association between cardiac valve calcification and 1-year mortality in diabetic patients after lower-extremity amputation. the investigator recruited consecutive patients who were admitted to the sun yat-sen memorial hospital for diabetic foot ulcers that needed amputation surgery. clinical characteristics of each patient and the laboratory examination were collected before surgery. cardiac valve calcification was assessed at baseline. this study obtained the survival status of patients within one year through outpatient follow-up and telephone follow-up. researchers compared the survival group to the mortality group to see if the mortality group had a higher prevalence of heart valve calcification.

Eligibility criteria:
inclusion criteria: * had echocardiography at baseline * with diabetic foot ulcers that required amputation after orthopedist's assessment exclusion criteria: * fractures due to traumatic reasons that required extremity amputation * amputation level below the ankle * severe sepsis that required vasoactive agent treatment * rheumatic heart disease * heart valve surgery history
sensitivity and specificity of ngal in an emergency room population

Conditions: Azotemia; Renal Insufficiency, Chronic; Renal Failure, Acute; Hydronephrosis

Summary: hypothesis: in patients that present to an urban emergency room, a single urine neutrophil gelatinase-associated lipocalin (ngal) measurement can classify their kidney disease as stable chronic kidney disease, acute tubular necrosis, urinary outlet obstruction or pre-renal azotemia.

the purpose of this study is to determine whether urinary ngal levels are able to distinguish the classical categories of renal disease. previous studies have strongly suggested that this protein marks those with fulminant renal dysfunction with greater sensitivity and time resolution than currently used markers. studies to date have been in highly selected populations: children and adults following cardiac surgery, infants with cardiovascular anomalies, and patients with known chronic kidney disease. demonstration of similarly robust sensitivity and specificity in a broad emergency room population would strengthen the conception of ngal as a marker of early or advancing kidney dysfunction. most importantly, if ngal can distinguish between types of renal disease at presentation in the er, it might have important implications regarding er management of these common presentations. for example, it could reduce diagnostic ambiguity and lag time from hours or days to seconds.

Eligibility criteria:
inclusion criteria: a. must be greater than or equal to 18 years of age b. must satisfy the following age and sex stratified serum creatinine levels: 1. men between ages 18 and 50 with serum creatinine greater than 1.2mg/dl 2. women between ages 18 and 50 with serum creatinine greater than 1.2mg/dl 3. men older than 50 with serum creatinine greater than 1.0mg/dl 4. women older than 50 with serum creatinine greater than 0.8mg/dl c. all pts greater than or equal to 18 years of age without kidney failure defined by b

Keywords: renal kidney lipocalin urine biomarker azotemia renal insufficiency, chronic renal failure, acute hydronephrosis
ibi3001 in participants with unresectable, locally advanced or metastatic solid tumors

Conditions: Locally Advanced Solid Tumor

Summary: this is a phase 1 multicenter, multi-regional, open-label, first-in-human study of ibi3001 in participants with unresectable, locally advanced or metastatic solid tumors. the purpose of this study is to identify the mtd/rp2d of ibi3001, and to explore the preliminary efficacy of ibi3001.


Eligibility criteria:
key inclusion criteria: 1. male or female participants ≥ 18 years old; 2. has an eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1; 3. has an anticipated life expectancy of ≥ 12 weeks; 4. adequate bone marrow and organ function: 5. at least 1 evaluable lesion according to response evaluation criteria in solid tumors (recist) version 1.1. for dose escalation , and 1 measurable lesion for dose expansion. 6. has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks. key exclusion criteria: 1. progressed or refractory to an adc that consists of an exatecan derivative that is a topoisomerase i inhibitor or intolerable with an adc that consists of exatecan; 2. plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study; 3. pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours); 4. gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment; 5. known symptomatic central nervous system (cns) metastases. 6. history of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; uncontrolled diseases; 7. history of endotracheal or gastrointestinal stent implantation; 8. ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention; 9. esophageal or gastric varices requiring immediate intervention; 10. not eligible to participate in this study at the discretion of the investigator; 11. do not have adequate treatment washout period before study drug administration. -
association between irisin, inflammatory markers and metabolic status in obese children with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2; Pediatric Obesity

Summary: the objective of this study was to investigate the association of irisin with inflammatory markers as well with metabolic and anthropometric parameters in children and adolescents with type 2 diabetes mellitus compared with healthy controls.

mexican children and adolescents previously diagnosed with type 2 diabetes mellitus according to the american diabetes association (ada) criteria were recruited and compared to healthy controls. the participants will undergo: * vital signs measurement (systolic and diastolic blood pressure, heart rate, respiratory rate) * anthropometric variables measurement (bmi, weight, waist circumference, hip circumference, body fat %) * laboratory studies: glucose, triglycerides, hdl-c, c reactive protein, irisin after statistical analyses the investigators will compare the relationship of irisin and the inflammatory profile and the anthropometric parameters of diabetic patients versus lean controls.

Eligibility criteria:
inclusion criteria: • have been previously diagnosed with t2dm according to the american diabetes association (ada) criteria . healthy controls were required to have: * normal weight according to the centers for disease control and prevention (cdc) criteria. * no metabolic abnormalities on blood samples * no previously diagnosed cardiometabolic diseases * not been using antihypertensive, lipid or glucose lowering medications exclusion criteria: * disapproval by the children's physician due to any at-risk medical condition known by the parents * use of drugs for high blood pressure, hyperglycemia, or dyslipidemia
ultrasound based acoustic radiation force impulse imaging

Conditions: Liver Fibrosis; Liver Inflammation

Summary: arfi (ultrasound-based acoustic radiation force impulse) will be used during ultrasound guided needle biopsy of the liver of children.

a new technique based on ultrasound, known as acoustic radiation force impulse (arfi) imaging is performed using standard approved ultrasound machines and transducers. the sound waves or impulses are generated in a different pattern and offer information on the stiffness of the tissue. this new technique will be evaluated for usefulness in diagnosing different liver conditions.

Eligibility criteria:
inclusion criteria: * 18 years of age or younger * scheduled to have a needle biopsy of the liver at 1. c.s. mott children's hospital or 2. dept. of radiology at the univ. of michigan hospital * scheduled to have an abdominal ultrasound to evaluate your liver (with no known liver disease) exclusion criteria: * none to list
genomics in michigan to adjust outcomes in prostate cancer (g-major) for men with newly diagnosed favorable risk prostate cancer

Conditions: Prostate Cancer

Summary: this study seeks to determine the clinical impact of gene expression classifier (gec) testing in prostate cancer care while also developing a pragmatic approach for improved gec clinical use and future study.

all patients in this study have received or will receive a score from the michigan urological surgery improvement collaborative's cancer of the prostate risk assessment (askmusic) scoring system, at the time of enrollment. askmusic is a risk calculator based on standard clinical and pathologic variables and is generally included as part of routine clinical care. the variables used in the risk calculator are prostate-specific antigen (psa), gleason score, number of positive core biopsies, number of negative core biopsies, and clinical stage. patients will be randomized to either an intervention arm or a control arm. in the control arm, the treating provider will review the askmusic score with the patient. in the intervention arm, the treating provider will review the askmusic and the gec score with the patient. biopsies obtained during the course of standard clinical care will be analyzed using one of the following gecs: decipher, prolaris or oncotype dx genomic prostate score. no additional biopsies will be obtained as part of this study. after reviewing the results, patients and their treating physicians will decide on a management strategy. long-term follow-up will be tracked through the michigan urological surgery improvement collaborative (music) registry.

Eligibility criteria:
inclusion criteria: * prostate cancer patients who have undergone diagnostic prostate biopsy in the past 9 months. * prostate biopsy tumor tissue (ffpr block) available for processing * age 18 years or older * psa \<20 ng/ml * grade group (gg) 1 cancer with \> 2 biopsy cores involved with cancer or gg2 cancer * ability to understand and the willingness to sign a written informed consent. a subject's legally acceptable representative may sign the consent form. exclusion criteria: * clinical (on digital rectal exam) or radiographic evidence (if mri performed) of t3 disease * nodal or metastatic prostate cancer (if staging imaging performed) * prior prostate cancer treatment, including prostatectomy, radiation therapy, or hormone therapy. * prior prostate gene expression classier testing

Keywords: biomarkers active surveillance gene expression classifier
evaluation of liver and cardiometabolic health benefits on low carbohydrate ketogenic diet

Conditions: Obesity; Fatty Liver; Ketogenic Dieting

Summary: to evaluate the impact of a low carbohydrate ketogenic diet (lckd) weight loss program and compare to the standard of care program established for patients with non-alcoholic fatty liver disease (nafld) on: (1) liver fat and liver stiffness scores, (2) lipid profile and insulin sensitivity; and (3) depression scores and quality of life, and (4) cardiometabolic measures such as cardiopulmonary exercise test (cpet) and transthoracic echocardiogram (tte).

this prospective pilot pragmatic trial will investigate the role of a lckd weight loss program for obese patients (bmi ≥30 kg/m2) and compare it to the group of known obese nafld patients who receive dietetic counseling as part of their standard of care in a dedicated nafld program. all participants (n=50) will be recruited at virginia commonwealth university (vcu). patients will do initial paperwork including questionnaires qol, eating disorder screen, depression screen: qol, eating disorder screen and depression screen. labwork: data will be collected from routine care labwork to include a fasting cholesterol panel, insulin, a1c and comprehensive panel (if they have not received these labs in the preceding 3 months), and at 6 and 12 months. a1c will be collected at 3,6,9 months as well (if a1c \>/=7), or just additionally at 6 months if a1c \<7 study labs will be collected: blood at 0, 3, 6 and 12 months urine, stool and saliva at 0, 1, 3 and 12 months fibroscan will be done at 0, 3, 6 and 12 months echo/cpet testing and room calorimetry will be offered and the patients agreeing to do this will have them done at 0, 3 and 12 months

Eligibility criteria:
inclusion criteria: * the inclusion criteria include patients aged 18 years and older, bmi ≥ 30, alt (alanine transferase) \> 19 (female) and \> 30 (male) or radiographic evidence of hepatic parenchymal disease and seen in either the pis weight loss clinic or a patient in the vcu nafld (non-alcoholic fatty liver disease) program. exclusion criteria: * patients will be excluded if they have known other liver disease such as viral hepatitis, autoimmune hepatitis, liver transplant, severely ill, weekly alcohol use (\>14 drinks in men and \>7 drinks in women), hiv, pregnant females, those\< 18 years, and prisoners.

Keywords: ketosis nafld obesity